Project Impact By Country Project Impact By CountryProject Impact By Country
Learn about PSI's models Learn about PSI's modelsLearn about PSI's models

Injectable Contraceptives

Injectable contraceptives are hormones delivered to a woman through an injection in her arm or buttocks. There are two types of injectable contraceptives: combined and progestin-only. Depending on the type, injectables last for one, two or three months before a new injection must be administered.

Injectable contraceptive (1-month) refers to combined injectable contraceptives, which contain both progestin and estrogen. They are administered once a month and are reversible (a woman can get pregnant once she stops using them).

Injectable contraceptive (2-month) is a progestin-only injectable containing NET-EN. They are administered every 2 months and are reversible.

Injectable contraceptive (3-month) is a progestin-only injectable containing DMPA. They are administered every 3 months and are reversible.

Unit of interventionOne injection

TypeShort-term contraceptive method

Effective life spanOne, two or three months (type dependent)

Target populationWomen of reproductive age (15-49)

Increased access to family planning helps women prevent unintended and high-risk pregnancies, contributes to the overall health of women and their children, and reduces the need for abortion. For more information about how PSI is empowering women and couples to lead healthier lives, visit our website at:

Model Overview

PSI’s estimates for the health impact of family planning use a methodology developed by Marie Stopes International (MSI) in the Impact 2 model (version 4). Please see for detailed methodology. PSI’s current approach for estimating the impact on child mortality is based on assumptions about changes in mortality risk for children under-five years of age with lengthening birth intervals. PSI is working with modelers from partner organizations to integrate new evidence and adopt a set of common assumptions across impact models for family planning.

PSI uses USAID’s couple years of protection (CYP) conversion factors to represent the estimated protection against unintended pregnancy provided by contraceptive methods during one year. PSI does not modify these conversion factors when estimating CYPs provided.

Service provision:

When a client directly receives a family planning method from a PSI or PSI-affiliated provider during a consultation, PSI claims 100% of the impact of that service.


When PSI distributes a family planning method but does not provide it directly to a client, PSI claims 90% of the impact of that product, to take into account supply chain wastage.


When a client is referred by PSI to a non-PSI service provider, such as the public sector, instead of providing the service itself, PSI claims 50% of the impact of that service. This impact is only attributed to PSI when the referral is confirmed with appropriate documentation.

Model Outputs (impact metrics)

Estimates of DALYs averted, deaths averted, CYPs provided, and unintended pregnancies averted represent the projected health impact of the intervention. It is projected because it has not been directly measured.

Examples based on injectable (1-month) distribution in Myanmar in 2015